Atossa Therapeutics Cash Flow From Operations vs. Current Valuation

YAG2 Stock   1.20  0.01  0.83%   
Based on Atossa Therapeutics' profitability indicators, Atossa Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Atossa Therapeutics' ability to earn profits and add value for shareholders.
For Atossa Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Atossa Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Atossa Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Atossa Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Atossa Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
Please note, there is a significant difference between Atossa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atossa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atossa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Atossa Therapeutics Current Valuation vs. Cash Flow From Operations Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Atossa Therapeutics's current stock value. Our valuation model uses many indicators to compare Atossa Therapeutics value to that of its competitors to determine the firm's financial worth.
Atossa Therapeutics is rated first in cash flow from operations category among its peers. It is rated first in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Atossa Therapeutics' earnings, one of the primary drivers of an investment's value.

Atossa Current Valuation vs. Cash Flow From Operations

Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Atossa Therapeutics

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(16.47 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Atossa Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
(59.13 M)
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Atossa Current Valuation vs Competition

Atossa Therapeutics is rated first in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is at this time estimated at about (105.64 Billion). Atossa Therapeutics has negative current valuation of (59.13 Million) making less than 1% of the industry.

Atossa Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Atossa Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Atossa Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Atossa Therapeutics' important profitability drivers and their relationship over time.

Use Atossa Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atossa Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atossa Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Atossa Therapeutics Pair Trading

Atossa Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Atossa Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atossa Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atossa Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atossa Therapeutics to buy it.
The correlation of Atossa Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atossa Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atossa Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atossa Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Atossa Therapeutics position

In addition to having Atossa Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Aggressive Defence Thematic Idea Now

Aggressive Defence
Aggressive Defence Theme
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Atossa Stock Analysis

When running Atossa Therapeutics' price analysis, check to measure Atossa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Therapeutics is operating at the current time. Most of Atossa Therapeutics' value examination focuses on studying past and present price action to predict the probability of Atossa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Therapeutics' price. Additionally, you may evaluate how the addition of Atossa Therapeutics to your portfolios can decrease your overall portfolio volatility.